The next big winner is:
Priority Review NDA filed for Probuphine, a 6 month slow release treatment for the millions addicted to pain meds and illicit drugs.
TTNP's patented ProNeura technology is also being advanced for chronic pain and Parkinson's.
April 30th approval triggers a $50 million milestone to TTNP.
A great day to load up.